

Ticket #:	Request Date:	Request Time:

PHYSICIAN CERTIFICATION PRIOR AUTHORIZATION FORM

A request for the patient identified below has been made for the dispensing of **Suboxone®/Subutex®**. Based on recent clinical information, we require more information before this prescription can be paid by the patient's health benefit plan. Please fill out the following information and return to us as indicated below:

A. Member Information Patient Name:		Plan Name/Plan ID:								
Patient ID:		Patient Date of Birth:			Patient Contact Phone #:					
В.	Physician Information									
	sician Name:		Physicia	ın Address:						
Phy	sician DEA #:	Physician Phone	#:			Physician Fax	#:			
Drug Name and Strength: Direction (SIG):			QTY and Days Supply:		NDC	#:				
C.	Pharmacy Information									
Pharmacy Name: NABP #:		P #:		Pharmacy Phone #:			Pharmacy Fax #:			
D.	Clinical Information (Please fill	out the following	informat	ion: circle a	ll that appl	y)				
Cor	nplete this section for Initiation	and Continuation	ı: (Refer t	to page 2 for	required do	ocuments and the	e prescri	ber's signature.)	
Che	ck one: Suboxone® Suboxone	outex® Dose:			Dire	ctions:				
Check one: □ Induction □ Stabilization □ Maintenance Induction Date: (required)/										
Ant	cipated length of therapy:									
1.	Is the patient pregnant or nursing	? If pregnant, expected date of delivery:// YE				YES	NO			
2.	Is this request for the treatment of	of opioid dependence?				YES	NO			
3.	Is this request for the treatment of	f pain?				YES	NO			
4.	Is the patient taking other opioids	the patient taking other opioids, tramadol or carisoprodol?				YES	NO			
5. Is the prescriber registered to prescribe Suboxone/Subutex under the Substance Abuse and Mental Health Services Administration (SAMHSA)?				YES	NO					
Init	ation of therapy or initial review	v: (Supporting doc	umentatio	on is required	for answe	rs to all the quest	tions.)			
						YES	NO			
2.	2. Has an initial drug screen been performed to verify presence of opiates and other substances?					YES	NO			
3.	Has the patient failed more than	one prior attempt v	with opiate	es agonist tre	eatment witl	hin the past 12 m	onths?		YES	NO
	If YES, provide date(s) of relapse	e(s):								
4.					YES	NO				
If YES, please list:										
5. What best describes the recovery environment for this patient? □ Supportive □ Unsupportive □ Toxic										
6.				YES	NO					
	If YES, specify:									
							(continu	uation on page	· #2)	

^{**}Please note that this form is to be completed by the prescribing physician. This form and its contents are permissible under HIPAA as the protected health information (PHI) contained in this letter is only being used for purposes related to the provision of treatment, payment and healthcare operations (TPO). HIPAA does restrict the communication of PHI with providers for TPO related purposes.

	iation of therapy or initial review: (Continued from page 1)		
7.	Has the patient been referred for a psychiatric evaluation if indicated?	YES	NO
8.	Has the patient signed a contract (attach) and committed to both pharmacologic and non-pharmacologic modalities of treatment?	YES	NO
	Date of next visit?		
Со	ntinuation of Therapy: (Supporting documentation is required for answers to all the questions.)		
1.	Is the patient compliant with pharmacologic therapy?	YES	NO
	Drug screen date: (please attach)		
2.	Is the patient compliant with non-pharmacologic therapy?	YES	NO
	Provide details (support type [group or individual], frequency of attendance, dates):		
		YES	NO
3.	How long has the patient been stable at the current dose?	YES	NO
4.	Is the patient ready to taper the dose at this time?	YES	NO
	If NO, provide rationale:		
	If YES, provide taper schedule:		
5.	Is the revised individual treatment plan reflecting follow-up at the most current office visit attached for review?	YES	NO
	Date of next office visit:		
Pri	or Authorization Standards for Review:		
	Prior authorization review is intended for office-based treatment of opioid dependency for individuals who meet the following		
	criteria:		
	With an adequate amount of psychosocial support; family/peers		
	 With a readiness for change and a personal commitment to live a drug-free lifestyle 		
	 With a willingness to comply with all elements of the treatment plan, including pharmacologic and non-pharmacologic aspects of the established protocol 		
	With consistent regular drug screens that are negative for opiates		
	With a willingness to abstain from illicit drugs		
	Helpful links:		
	SAMHSA recommendations: http://www.samhsa.gov		
	National Library of Medicine for Clinical Guidelines for Use of Buprenorphine in the Treatment of Opioid Addiction		
	http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=hssamhsatip∂=A72248		

Authorized Medical Signature:					
Telephone:	Date:				

When Completed Return To:

MC-Rx Clinical Division, 1267 Professional Parkway, Gainesville, GA 30507 1-866-965-Drug (3784) / Fax # 866-999-7736

^{**}Please note that this form is to be completed by the prescribing physician. This form and its contents are permissible under HIPAA as the protected health information (PHI) contained in this letter is only being used for purposes related to the provision of treatment, payment and healthcare operations (TPO). HIPAA does restrict the communication of PHI with providers for TPO related purposes.